Vacasa Stock (NASDAQ:VCSA), Trade Ideas

Vacasa

Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.

News

Price Target

Initiation

Travel

Small Cap

Analyst Ratings

Trading Ideas

General

TRIP

VCSA

Goldman Sachs analyst Benjamin Miller took a look at online travel stocks, now that the industry has gone past COVID-19 and increasingly moving beyond the pent-up demand post-pandemic. 

TripAdvisor, Clear Secure See Growth, Vacasa Awaits Clarity, Says Analyst About These Online Travel Companies

Penny Stocks

Intraday Update

Markets

ALGM

BRLT

WOOF

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#39;s opinion to trust.

This Analyst With 86% Accuracy Rate Sees Around 240% Upside In Vacasa - Here Are 5 Stock Picks For Last Week From Wall Street&#39;s Most Accurate Analysts

Movers

AMBI

APEI

BLCM

BOXD

CASA

COOK

CXAI

CYAD

EBIX

ELEV

ELYS

Euda Health Holdings Limited - Ordinary Shares

EUDA

FINV

FRPT

HUBC

INPX

IXHL

JNCE

KRBP

LUNA

LYLT

MOGU

MULN

NMTC

ONCS

OPEN

PACW

PRDS

SMAR

SMIH

STLD

TCBP

THMO

TORO

VNRX

Gainers


	ThermoGenesis Holdings, Inc.  (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.


Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Vacasa Inc

RVTY

Revvity Announced The Launch Of The Auto-pure 2400 Liquid Handler From Allsheng For Use With The T-SPOT.TB Test

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and maintains $50 price target.

Reiteration

DAWN

HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $50 Price Target

Buybacks

Synchrony Financial Board Approved $1B Of Incremental Share
Repurchase Authorization

Standard Lithium Announce That It Has Successfully Commissioned And Validated The Performance Of The Largest Continuously-operating Direct Lithium Extraction Equipment In North America

1Q Net sales up 2.7% and organic sales up 3.8% driven by Service net sales up 5.8% with organic sales up 6.5%
&bull;1Q GAAP EPS up 8.9% and adjusted EPS up 10.0% with GAAP operating profit margin expansion of 50 basis points and adjusted operating profit margin expansion of 80 basis points
&bull;1Q New Equipment orders down 10%, backlog down 2%, ~flat at constant currency
&bull;1Q Mod orders up 13%, backlog up 14%, up 15% at constant currency
&bull;Maintenance portfolio units increased 4.1%
&bull;1Q GAAP cash flow from operations of $171 million; adjusted free cash flow of $155 million
&bull;1Q share repurchases of $300 million
&bull;Updated full-year outlook1; increasing adjusted EPS to $3.83 to $3.90 and full year share repurchase target to $1 billion

Earnings

OTIS

Otis Q1 New Equipment Orders -10%, New Equipment Backlog -2%,

<div>System-wide comparable RevPAR, on a currency neutral basis, is projected to increase between&nbsp;2.0 percent&nbsp;and&nbsp;4.0 percent&nbsp;compared to the&nbsp;second quarter&nbsp;of 2023.&nbsp;Adjusted EBITDA is projected to be between&nbsp;$890 million&nbsp;and&nbsp;$910 million.</div>

Guidance

Hilton Expects Q2 Adjusted EPS Of $1.80-$1.86, Est $1.88

Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.47 by 4.26 percent. The company reported quarterly sales of $170.901 million which beat the analyst consensus estimate of $149.350 million by 14.43 percent. This is a 9.96 percent decrease over sales of $189.796 million the same period last year.

Earnings Beats

PPBI

Pacific Premier Bancorp Q1 2024 Adj EPS $0.49 Beats $0.47 Estimate, Sales $170.901M Beat $149.350M Estimate

Contracts

Tutor Perini's Subsidiary, Black Construction Corporation Won Three Projects In Diego Garcia Totaling $54.5M

Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.87 by 1.15 percent. This is a 10 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $3.437 billion which missed the analyst consensus estimate of $3.455 billion by 0.53 percent. This is a 2.72 percent increase over sales of $3.346 billion the same period last year.

Earnings Misses

Otis Worldwide Q1 2024 Adj EPS $0.88 Beats $0.87 Estimate, Sales $3.437B Miss $3.455B Estimate

Owens Corning Expects Q2 Net Sales To Be Stable Y/Y, While Generating About 20% EBIT Margins For Its Existing Businesses

<div>System-wide comparable RevPAR, on a currency neutral basis, is still projected to increase between&nbsp;2.0 percent&nbsp;and&nbsp;4.0 percent&nbsp;compared to 2023.&nbsp;Net unit growth, excluding the effect of the planned acquisition of the Graduate Hotels brand, is projected to be between&nbsp;6.0 percent&nbsp;and&nbsp;6.5 percent.</div>

Hilton Boosts FY24 Adj EPS Outlook From $6.80-$6.94 To $6.89-$7.03, Est $7.12

WIIM

Synchrony Financial shares are trading lower following Q1 financial results.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $150 price target.

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target

Third Quarter&nbsp;FY24&nbsp;Outlook
For the&nbsp;third quarter&nbsp;of fiscal 2024, the company expects net sales of approximately&nbsp;$4.0 billion. GAAP EPS from continuing operations are expected to be approximately&nbsp;$1.71, up&nbsp;2%&nbsp;year over year, with adjusted EPS of approximately&nbsp;$1.85, up&nbsp;5%&nbsp;year over year.&nbsp;Third quarter&nbsp;guidance&nbsp;includes a&nbsp;$0.15&nbsp;year-over-year headwind from tax and currency exchange rates.

TE Connectivity Expects Q3 Net Sales of $4B Vs $4.11B Est, Adj EPS of $1.85 Vs $1.92 Est

Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) reported quarterly earnings of $3.59 per share which beat the analyst consensus estimate of $3.08 by 16.56 percent. This is a 29.6 percent increase over earnings of $2.77 per share from the same period last year. The company reported quarterly sales of $2.30 billion which beat the analyst consensus estimate of $2.28 billion by 0.88 percent. This is a 1.33 percent decrease over sales of $2.33 billion the same period last year.

Owens-Corning Q1 Adj. EPS $3.59 Beats $3.08 Estimate, Sales $2.30B Beat $2.28B Estimate

Bunge Sees FY24 Adj EPS Of $9.00 Vs. $9.39 Est.

Vertiv Holdings Sees Q2 Revenue Of $1.90B-$1.95B (Vs. $1.90B Cons.), Adj. EPS Of $0.53 - $0.57 (Vs. $0.55 Est.)

Synchrony Financial Purchase Volume Increased 2%, Loan Receivables Increased 12%, Net Interest Margin Decreased 67 bps

Annual Guidance for 2024
Thermo Fisher is raising its full year revenue and adjusted EPS guidance to reflect stronger operational performance. The company is raising its revenue guidance to a new range of $42.3 to $43.3 billion versus its previous guidance of $42.1 to $43.3 billion. The company is raising its adjusted EPS guidance to a new range of $21.14 to $22.02 versus its previous guidance of $20.95 to $22.00.
&nbsp;

Thermo Fisher Scientific Raises FY2024 Outlook: Adj EPS $21.40-$22.02 ($20.95-22.00 Prior) vs $21.53 Est; Sales $42.3B-$43.3B ($42.1B-43.3B Prior) vs $42.83B Est

TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.83 by 1.64 percent. This is a 12.73 percent increase over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $3.967 billion which beat the analyst consensus estimate of $3.956 billion by 0.27 percent. This is a 4.64 percent decrease over sales of $4.160 billion the same period last year.

TE Connectivity Q2 2024 Adj EPS $1.86 Beats $1.83 Estimate, Sales $3.967B Beat $3.956B Estimate

Analyst Benjamin Miller CFA of Goldman Sachs reiterated a Hold rating on Vacasa (VCSA – Research Report), with a price target of $11.00. Benjamin M...

Maintaining Neutral: Vacasa's Hold Rating Amidst Market Challenges and Cost Control Efforts

Vacasa (VCSA – Research Report) received a Hold rating and price target from JMP Securities analyst Nicholas Jones CFA today. The company's shares ...

Vacasa (VCSA) Receives a New Rating from JMP Securities

BTIG analyst Jake Fuller has maintained their neutral stance on VCSA stock, giving a Hold rating today. Jake Fuller's rating is based on a confluen...

Vacasa's Performance Pressures Justify Cautious Hold Rating Amidst Market Headwinds

In a report released today, Justin Patterson from KeyBanc maintained a Hold rating on Vacasa (VCSA – Research Report). The company's shares closed ...

KeyBanc Reaffirms Their Hold Rating on Vacasa (VCSA)

Vacasa (VCSA) has disclosed a new risk, in the Technology category. Vacasa faces significant risks with the integration of artificial intelligence ...

New Technology Risk for Vacasa – What's the Latest?

Vacasa Inc (VCSA) stock is down -71.32% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives VCSA stock a score of  33 out of a possible 100. That rank is primarily influenced by a short-term technical score of 1. VCSA's rank also include

Is Vacasa Inc (VCSA) Stock Worth a Buy Monday?

Vacasa (VCSA) just unveiled an announcement. Kimberly White resigned from the Board of Directors at Vacasa, Inc. on March 5, 2024, after serving le...

Kimberly White Resigns from Vacasa Board Amid Ownership Shift

Vacasa Inc (VCSA) stock is lower by -74.05% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives VCSA stock a score of  35 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 1. VCSA's rank also inclu

Is Vacasa Inc (VCSA) Stock a Smart Value?

Vacasa: Changing The Sector's Paradigm Requires Patience

Warning: VCSA is at high risk of performing badly

Legal

Press Releases

(SPAC) Special Purpose Acquisition Investigation: PWP, PRCH, VCSA, SKIL - Contact Shareholder Rights Law Firm Johnson Fistel

Vacasa to Announce Second Quarter 2023 Financial Results on August 8, 2023

Vacasa Announces Second Quarter 2023 Financial Results

Vacasa Announces Reverse Stock Split

Vacasa to Announce Third Quarter 2023 Financial Results on November 7, 2023

Vacasa Announces Third Quarter 2023 Financial Results

Matterport Signs Multi-Year Partnership with Vacasa to Provide Digital Twins for International Portfolio of Vacation Homes

Vacasa to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Vacasa Announces Fourth Quarter and Full Year 2023 Financial Results

MTTR

PRCH

SKIL

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Despegar.com

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share